


Product Name : Izorlisib
Cat. No. : PC-73424
CAS No. : 1007207-67-1
Molecular Formula : C₁₅H₁₉N₇O₃S
Molecular Weight : 377.423
Target : PI3K
Solubility : 10 mM in DMSO



Biological Activity

Izorlisib (MEN1611, CH5132799) is a potent, selective, orally available **class I PI3K** inhibitor with IC₅₀ of 14/120/400/36 nM against **PI3Kα/β/δ/γ**, respectively.

Izorlisib (CH5132799) shows less inhibition of class II PI3Ks, class III PI3k and mTOR and also no inhibitory activity (IC₅₀ >10 μM) against 26 protein kinases.

Izorlisib (CH5132799) exhibits more inhibitory activities against PI3Kα with oncogenic mutations E542K (IC₅₀ = 6.7 nM), E545K (IC₅₀ = 6.7 nM) and H1047R (IC₅₀ = 5.6 nM) than wild-type PI3Kα.

Izorlisib (CH5132799) effectively suppresses phosphorylation of Akt PRAS40 and FoxO1/3a and phosphorylation of downstream factors, including S6K, S6 and 4E-BP1 in breast cancer KPL-4 cells.

Izorlisib (CH5132799) shows potent in vivo antitumor activity in several different xenograft models with PIK3CA mutations.

References

Ohwada J, et al. *Bioorg Med Chem Lett*. 2011 Mar 15;21(6):1767-72.

Tanaka H, et al. *Clin Cancer Res*. 2011 May 15;17(10):3272-81.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com